Official inauguration of the Apollon Formularies International Institute of Cancer and Chronic Pain
LONDON, February 3, 2022 /PRNewswire/ — Apollon Formularies plc (AQSE: APOL, “Apollon” or the “Company”), an international medical cannabis pharmaceutical company based in the UK and traded on the Aquis Stock Exchange Growth Market, is pleased to announce that it has officially opened its International Institute of Cancer and Chronic Pain (“ICCPI”) in the Jamaican capital and the country’s main medical center, kingston. The facility will specialize in complementary and alternative medical (“CAM”) treatments for cancer patients. These treatments will include Apollon’s medical cannabis products.
This facility allows Apollon to expand its patient treatment program for Jamaican and international medical patients, and at the same time generate additional revenue for the company.
Apollon is pleased to add that the Society is experiencing a demand from international patients who wish to be treated in Jamaica and will admit its second British patient in mid-February 2022.
ICCPI also provides the opportunity to collect invaluable patient data regarding the company’s medical cannabis formulations.
In December 2021Apollon welcomed its first cancer patients to its existing facilities in Jamaica and is now able to provide expanded access through two facilities located in Negril and kingston. In addition to treating international and local Jamaican patients, ICCPI physicians will soon initiate clinical trials of Apollon’s proprietary medical cannabis products through Apollon’s research and development license under the supervision of the Ministry of Health and Welfare Jamaica.
Paul BurqueCEO of Apollon Formularies Jamaica, commented: “Our International Cancer Institute is one of a kind and I am proud to see our hard work paying off. Following our remarkable 3D cell culture test results and the expansion of our production facility, this next step will help Apollon compete globally while providing our patients with the expert treatment and care they need.”
Hon. Dr Norman Dunn MP, Minister of State for the Department of Industry, Investment and Trade said: “It gives me great pleasure to be part of today’s landmark occasion for Apollon Formularies as you open Jamaica’s first International Cancer and Chronic Pain Institute, which was established to offer free herbal medicines and to conduct clinical trials of cancer treatment formulations.all accounts, their formulations have undergone rigorous third-party testing from esteemed pharmaceutical testing laboratories.I particularly commend the Dr. stephen barnhill and Dr. Dingel Spence, Paul Burque and the rest of the Apollon Formularies team for your vision, tenacity and entrepreneurial spirit.”
Doctor stephen barnhillCEO of Apollon Formularies, said: “I am pleased to see the progress we have made as a company come to fruition with the official opening of this impressive cancer institute. The facility will give us the ability to admit patients and use our formulations to treat common cancers I would like to take this opportunity to thank the team on the ground Jamaica who helped make this happen.”
The Directors of the Company accept responsibility for the content of this announcement.
On Apollo and Apollo Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in UK. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollo Jamaica is licensed by the Jamaican government’s Cannabis Licensing Authority (CLA) to cultivate, research and develop, process and sell therapeutic medical cannabis products that include legal medical cannabis to treat various illnesses under medical supervision. Apollo and Apollo Jamaica are parties to a commitment agreement under which Apollon is entitled to 95% of the Apollo Jamaica net profits, and pursuant to a share pledge agreement which includes Stephen D. BarnhillMD, Apollon will be awarded the entire 49% interest in Apollo Jamaica owned by Dr. Barnhill, which is the maximum stake in a medical cannabis company allowed to be owned by a non-Jamaican, after the CLA approved the divestment.